Equillium is hoping that unmet medical need and long-term efficacy will persuade the US Food and Drug Administration to approve itolizumab for acute graft-versus-host disease (aGVHD) despite its Phase III trial failing to meet its primary endpoint and a key secondary endpoint.
Key Takeaways
- Equillium said the Phase III EQUATOR trial missed the primary and a key secondary endpoint in first-line treatment of acute GVHD while showing longer-term efficacy.
The La Jolla, CA-based biotech said 27 March that the Phase III EQUATOR study comparing itolizumab against placebo did not show statistical significance on the primary endpoint of complete response...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?